Search

Home > Diabetes Knowledge into Practice Podcast > EASD 2021 | With Prof. Stephen Bain


	Podcast:		Diabetes Knowledge into Practice Podcast
	Episode:		EASD 2021 \| With Prof. Stephen Bain
	Category:		Health
	Duration:		00:14:56
	Publish Date:		2021-10-08 10:41:52
	Description:		This week we have more congress highlights from the 2021 annual meeting of the European Association for the Study of Diabetes (EASD), held online from the 28th September to the 1st October. Listen for commentary from Prof. Steve Bain on highlights including: - Results from the TriMaster study - Cardiovascular events with semaglutide with and without metformin (post-hoc analysis of SUSTAIN 6 and PIONEER 6) - More results from the SURPASS program - Intra-organ fat content during weight loss-induced remission of type 2 diabetes in people with normal or raised BMI (data from ReTUNE and DiRECT) For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. Disclosures: Professor Stephen Bain declares no relevant financial relationships within the past 12 months. References: Angwin C, et al. TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol. BMJ Open. 2020 Dec 21;10(12):e042784. Husain M., et al. Semaglutide reduced cardiovascular events regardless of metformin use: a post hoc exploratory subgroup analysis of SUSTAIN 6 and PIONEER 6. Abstract 21 presented at the 57th Annual Meeting of the European Association for the Study of Diabetes, 27 September – 1 October 2021, virtual. Diabetologia 64, 1–380 (2021). Taylor R, et al. Intra-organ fat content during weight loss-induced remission of type 2 diabetes in people with normal or raised BMI. Abstract 110 presented at the 57th Annual Meeting of the European Association for the Study of Diabetes, 27 September – 1 October 2021, virtual. Diabetologia 64, 1–380 (2021). Target Audience This educational activity is intended for an international audience of non-US and non-UK HCPs. Funding This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
	Total Play:		0